Recursion Pharmaceuticals (RXRX) revenue breakdown
By product, Operating revenue is the largest at 99% of fiscal 2025 revenue, growing 87% a year over 6 years.
By region, United States is the largest at 53% of fiscal 2025 revenue; United Kingdom grew fastest, 3013% a year over 1 years.
Revenue by product
Fiscal years, as Recursion Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $75M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Operating revenue | $2M | $3M | $10M | $40M | $44M | $58M | $74M | 99% |
| Grant revenue | $608,000 | $549,000 | $178,000 | $162,000 | $699,000 | $351,000 | $425,000 | 1% |
Revenue by region
Fiscal years, as Recursion Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $75M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| United States | $44M | $57M | $39M | 53% |
| United Kingdom | — | $1M | $35M | 47% |
| Other | $769,000 | $327,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RXRX.
Open RXRX in InvestinglyQuestions
Where does Recursion Pharmaceuticals make its money?
In fiscal 2025, by product: Operating revenue $74M, Grant revenue $425,000.
From Recursion Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.